Anlotinib in patients with recurrent platinum resistant/refractory ovarian cancer: a prospective, single arm, phase II study.

Wenbin ShenChuyu JingWenjuan TianWei ZhangYulan RenBoer ShanHuaying Wang

Published in: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society (2023)

Anlotinib showed antitumor activity with an acceptable safety profile in patients with platinum resistant/refractory ovarian cancer, and it might be a potential treatment in this population.

Keyphrases

phase ii study
open label
locally advanced
randomized controlled trial
squamous cell carcinoma
human health
risk assessment
climate change